NCT05985668 Towards Improved Diagnostics for Suspected Platelet Function Disorders
| NCT ID | NCT05985668 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Region Stockholm |
| Condition | Platelet Function Disorder |
| Study Type | OBSERVATIONAL |
| Enrollment | 140 participants |
| Start Date | 2023-09-05 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 140 participants in total. It began in 2023-09-05 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to improve platelet function testing during bleeding investigations. To this end, the study will evaluate the diagnostic accuracy of novel platelet function tests in patients with confirmed or suspected platelet function disorders. Study participants will be recruited from patients that are referred to or treated at the Coagulation Unit, Karolinska University Hospital, and Pediatric Coagulation Unit, Astrid Lingren Children's Hospital.
Eligibility Criteria
Inclusion Criteria, known defects: * Known platelet function disorder under follow-up at Karolinska University Hospital (genetic or functional assay) * High likelihood of platelet function disorder (aberrant screening test with inheritance) * Family investigation for platelet disorder Exclusion Criteria, known defects:: * Antiplatelet or anticoagulant drugs * vWF:GPIb below 0.40 IU/mL * Hematocrit below 0.35 or above 0.50 * Other coagulation disorder Inclusion Criteria, suspected platelet function disorder: * Bleeding investigation at Karolinska University Hospital Exclusion Criteria, suspected platelet function disorder:: * Antiplatelet or anticoagulant drugs * vWF:GPIb below 0.40 IU/mL * Hematocrit below 0.35 or above 0.50 * Other coagulation disorder
Frequently Asked Questions
Who can join the NCT05985668 clinical trial?
This trial is open to participants of all sexes, aged 12 Months or older, studying Platelet Function Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05985668 currently recruiting?
Yes, NCT05985668 is actively recruiting participants. Visit ClinicalTrials.gov or contact Region Stockholm to inquire about joining.
Where is the NCT05985668 trial being conducted?
This trial is being conducted at Stockholm, Sweden.
Who is sponsoring the NCT05985668 clinical trial?
NCT05985668 is sponsored by Region Stockholm. The trial plans to enroll 140 participants.